Search Within

Susan J McCall

Formats
  1. Meeting Abstract (9)
  2. Journal Article (6)
  3. Research Letter (1)
Groups
  1. Advanced Practice Providers (16)
  2. Department of Medicine (16)
  3. Hematologic Malignancies, Division of (16)
  4. Nursing (16)
  5. Center for Hematologic Malignancies (15)
  6. Lymphoma (14)

More Groups

People
  1. Craig Moskowitz (14)
  2. Matthew Matasar (13)
  3. Alison Moskowitz (12)
  4. Heiko Schoder (12)
  5. Anas Younes (11)
  6. Andrew Zelenetz (11)

More People

Years
  1. 2021 (1)
  2. 2019 (1)
  3. 2018 (2)
  4. 2017 (4)
  5. 2016 (3)
  6. 2015 (3)

More Years

Publications
  1. Blood (9)
  2. Hematological Oncology (2)
  3. Annals of Oncology (1)
  4. British Journal of Haematology (1)
  5. Haematologica (1)
  6. Lancet Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. Wiley Blackwell (2)
  3. Elsevier Science, Inc. (1)
  4. Ferrata Storti Foundation (1)
  5. John Wiley & Sons (1)
  6. Nature Publishing Group (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schòˆder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Bantilan, K. S.; Verwys, S. L.; McCall, S. J.; Yahalom, J.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save